Drug Trial News

RSS

USC researchers receive $4 million to test psychedelic therapy and mindfulness for depression

A team of USC researchers has received an up to $4 million award from the Advanced Research Projects Agency for Health (ARPA-H) to conduct a clinical trial of psychedelic therapy and mindfulness training for depression.

6 Oct 2026

Experimental cancer drug works differently than researchers originally thought

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

6 Oct 2026

Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026

ASAC trial reveals aspirin fails to improve metastatic colorectal cancer survival

Colorectal cancer is one of the most common cancers worldwide, and up to half of patients develop liver metastases during the course of their disease.

5 Oct 2026

Tirzepatide cuts fat mass by 35% while preserving skeletal muscle

Tirzepatide cuts body fat while preserving skeletal muscle in real-world study

2 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

NIH-funded trials will test pregnenolone for addiction and depression

Center for BrainHealth investigator Francesca Filbey, PhD, and UTSW investigator Sherwood Brown, MD, PhD, have secured two awards from the National Institutes of Health (NIH) to fund two major collaborative studies investigating whether the naturally occurring neurosteroid pregnenolone can help treat substance use disorders and co-occurring depression.

1 Oct 2026

New trial tests if diet can reduce bipolar depression symptoms

A clinical trial is set to test whether diet could help reduce depressive symptoms in people with bipolar disorder, comparing a high fat, low carbohydrate diet with standard NHS healthy eating advice.

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Policy review demands better quality of life data in cancer clinical trials

A new policy review from Common Sense Oncology (CSO) and the European Organisation for Research and Treatment of Cancer (EORTC) calls for quality of life data to play a more central role in clinical trials evaluating adjuvant cancer treatments.

1 Oct 2026

Weekly cisplatin fails to reduce acute toxicity in advanced head and neck cancer

Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer.

29 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Triple combination therapy trial for HR+/HER2− breast cancer halts early due to toxicity concerns

HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up to 60% of patients derive no clinical benefit from these agents, underscoring the urgent need for more effective therapeutic strategies.

28 Sep 2026

New trial aims to evaluate chemotherapy benefit for ER+/HER2- breast cancer patients

The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence.

24 Sep 2026

A 30-day benznidazole regimen offers safer Chagas disease treatment option

A 30-day course of benznidazole taken once a day could offer people with chronic Trypanosoma cruzi infection a safer and more practical option than the current standard treatment, taken twice a day for 60 days.

22 Sep 2026

EVITA clinical trial evaluates oral vitamin C for pre-cancerous blood disorders

Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off.

21 Sep 2026

Daily vitamin C may benefit pre-cancerous blood disorder patients

Vitamin C is an essential nutrient that supports immune function, promotes wound healing and protects cells from molecular damage.

21 Sep 2026

Quotient Sciences proprietary AI-enhanced solution optimizes formulation in clinical study

Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorithm selected modified-release formulation compositions and doses during the trial.

From Quotient Sciences 18 Sep 2026

UCSF researchers urge more convincing placebos in psychedelic trials

UC San Francisco researchers are weighing in on one of the biggest challenges in psychedelic science, arguing that clinical trials need more convincing placebo treatments to better measure the drugs' true effects.

16 Sep 2026